Eleven P15 develops genetic and biomarker solutions for early detection and treatment of idiopathic pulmonary fibrosis (IPF). The company creates biomarkers that identify IPF before symptoms appear and pursues genetically‑targeted therapies to halt disease progression. Their work integrates expertise in IPF genetics, mucus biology, and biomarker research to enable preventative and therapeutic strategies for this currently incurable condition.
Funding
Funding not disclosed
Founders
Product
Problem
Idiopathic pulmonary fibrosis (IPF) is a progressive, incurable lung disease that is often diagnosed at an advanced stage, limiting treatment options and leading to poor patient outcomes. Early detection is hampered by the lack of reliable, non‑invasive biomarkers, and existing therapies are not tailored to the genetic drivers of the disease.
Solution
Eleven P15 focuses on discovering and validating molecular biomarkers that can identify IPF at its earliest stages, enabling timely clinical intervention. The company integrates genomic data, mucus biology insights, and clinical research to pinpoint genetic variants and molecular signatures associated with disease onset and progression. By linking these biomarkers to genetically‑targeted therapeutic candidates, Eleven P15 aims to develop precision medicines that address the underlying causes of IPF rather than just its symptoms. The approach combines high‑throughput omics analyses with translational validation to accelerate the pipeline from biomarker discovery to drug development, ultimately supporting earlier diagnosis and personalized treatment strategies for at‑risk patients.
Target Audience
Primary customers include pharmaceutical and biotech companies seeking IPF biomarkers and precision‑medicine partners, as well as clinical research organizations conducting early‑stage IPF trials.
Features
- Identification of blood‑based and airway‑derived biomarkers linked to early IPF pathology
- Integration of IPF genetic risk loci with functional mucus biology studies to uncover disease mechanisms
- High‑throughput genomics and proteomics platforms for rapid candidate discovery
- Validation pipeline that correlates molecular signatures with clinical outcomes in patient cohorts
- Development of genetically‑targeted therapeutic candidates aligned with identified biomarkers
- Collaborative framework that combines academic expertise and industry resources for translational research